Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

Oruka Therapeutics announced it will report Week 16 data for ORKA-001 from the EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on October 26, 2026. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Previously announced Week 28 data from the EVERLAST-A trial showed positive results with PASI 100 reaching 71.4% and PASI 90 reaching 87.3% without additional dosing after Week 4.